COST-EFFECTIVENESS OF ESCALATING TO NATALIZUMAB OR SWITCHING AMONG IMMUNOMODULATORS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：4
|
作者：
Furneri, G. [1 ]
Santoni, L. [2 ]
Ricella, C. [2 ]
Prosperini, L. [3 ]
机构：
[1] EBMA Consulting, Melegnano, Italy
[2] Biogen, Milan, Italy
[3] Sapienza Univ, Dept Neurol & Psychiat 3, Rome, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2588
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM71
引用
收藏
页码：A695 / A695
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Santoni, Laura
    Ricella, Chiara
    Prosperini, Luca
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
  • [2] Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
    Gianluca Furneri
    Laura Santoni
    Chiara Ricella
    Luca Prosperini
    BMC Health Services Research, 19
  • [3] COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIA
    Matveev, N., V
    Sabanov, A., V
    Luneva, A., V
    VALUE IN HEALTH, 2014, 17 (03) : A60 - A60
  • [4] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia
    Lasalvia, Pieralessandro
    Hernandez, Fabian
    Castaneda-Cardona, Camilo
    Andres Cuestas, J.
    Rosselli, Diego
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 13 - 18
  • [5] COST-EFFECTIVENESS OF ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Kohn, Christine G.
    Costales, Victoria
    Coleman, Craig I.
    Young, Dan
    Limone, Brendan L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1413 - 1414
  • [6] Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
    Stephanie R. Earnshaw
    Jonathan Graham
    MerriKay Oleen-Burkey
    Jane Castelli-Haley
    Kenneth Johnson
    Applied Health Economics and Health Policy, 2009, 7 (2) : 91 - 108
  • [7] Cost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
    Earnshaw, Stephanie
    Graham, Jonathan
    Oleen-Burkey, MerriKay
    Castelli-Haley, Jane
    Johnson, Kenneth
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2009, 7 (02) : 91 - 108
  • [8] Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden
    O'Day, Ken
    Meyer, Kellie
    Stafkey-Mailey, Dana
    Watson, Crystal
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 295 - 302
  • [9] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
  • [10] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
12345